What we're reading, August 31, 2016: 51% of Americans have a negative view of the pharmaceutical industry; the CDC is running out of funds to fight the Zika virus; and Pennsylvania chooses 3 private companies to manage Medicaid plans.
A Gallup poll has found that just 28% of Americans have a positive view of drug makers, while 51% have a negative view. According to STAT, the only business sector included in the survey that the American public holds in lower esteem is the federal government. Ongoing controversy over the rising cost of drugs has overshadowed advances made by the pharmaceutical industry with new medicines treating cancer and curing hepatitis C. The pharmaceutical industry registered a net positive rating of negative 23, but the healthcare sector didn’t fare much better with a rating of negative 20.
The coffers for fighting the Zika virus are running dry. CDC Director Tom Frieden, MD, MPH, announced Tuesday that the CDC is out of money to fight Zika and that Congress needs to “do something,” reported The Hill. Almost all of the $222 million borrowed from HHS has been spent or budgeted, with half going to state and local health agencies and the rest going to development of new diagnostic tests, public outreach efforts, and staffing to deal with outbreaks in Puerto Rico and Florida.
Private companies will manage Medicaid plans for 420,000 people in Pennsylvania. The contracts with the 3 companies are part of the state’s overhaul of how nursing home stays, home care, and other supports for the elderly and physically disabled are paid for, reported The Philadelphia Inquirer. The contracts are part of a new program called Community HealthChoices and it supplements managed physical and mental health care for Medicaid beneficiaries, as well as covers people who are eligible for both Medicaid and Medicare.
Telephone Follow-Up on Medicare Patient Surveys Remains Critical
January 16th 2025Including a telephone component in Medicare Consumer Assessment of Healthcare Providers and Systems survey administration continues to be valuable because telephone responses comprise a substantial portion of responses for several underserved groups.
Read More
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More
Health Equity & Access Weekly Roundup: January 11, 2025
January 11th 2025ACA enrollment rate hits a milestone, though IRA subsidies may not extend beyond 2025; network adequacy standards fail to translate into efficient access to mental health care for Medicaid enrollees; research examines racial disparities in postpartum hypertension and vaccine uptake.
Read More